{
  "docId": "019de518-6502-70bc-9a44-c6a9c7f323b5",
  "docSlug": "4230ce80abe7092521a593effe59cbcd",
  "documentTitle": "Oculis | Investor Presentation Deck | 48 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 48,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "timeline",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de518-6502-70bc-9a44-c6a9c7f323b5/27",
  "deckHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5",
  "deckJsonHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5.json",
  "deckAnchorHref": "/decks/019de518-6502-70bc-9a44-c6a9c7f323b5#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.57,
        "w": 0.799,
        "x": 0.155,
        "y": 0.299
      },
      "kind": "diagram",
      "text": "1983 Cyclosporine¹ 1998 First anti-TNF: Infliximab² Etanercept² 2002 Cyclosporine¹ RESTASIS® 2024 Topical anti-TNF OCS-02 (Licaminlimab) eye drop in Phase 2b 26 years Global Sales: ENBREL®: $9.4B (2015)3 REMICADE®: $8.1B (2015)3 HUMIRA®*: $21.6B (2022)4 19 years",
      "attrs": {},
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "668b0745-b989-44b6-b2d7-8b9257ea6e76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.118,
        "x": 0.852,
        "y": 0.047
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b38449e-1fe2-4876-ad65-baaed617d1cc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.17,
        "x": 0.026,
        "y": 0.757
      },
      "kind": "list",
      "text": "TOPICAL DRY EYE TREATMENTS",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97427f3e-7dd2-4674-a200-401192357221",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.026,
        "y": 0.222
      },
      "kind": "list",
      "text": "SYSTEMIC INFLAMMATORY DISEASE TREATMENTS",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a771ff70-a9c4-47d3-ab39-cceb0d0d3d89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.944,
        "x": 0.026,
        "y": 0.918
      },
      "kind": "source-note",
      "text": "* Humira indicated as systemic treatment for posterior, pan-, and intermediate uveitis. DED (Dry eye disease). 1. Yavuz B, et al. Sci World J. 2012;2012:194848. 2. Leone GM, et al. J Clin Med. 2023;12(4)1630. 3. Lindsley CW. ACS Chem Neurosci. 2016;7(7):842-843. 4. Mikulic M. Leading pharmaceutical products by sales worldwide in 2022. Statista. Published August 30, 2023. Accessed February 20, 2024. Available at: https://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/#statisticContainer.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a10fc0dd-de8b-4afc-af41-544318a0f102",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.019,
        "w": 0.249,
        "x": 0.026,
        "y": 0.083
      },
      "kind": "title",
      "text": "The rise of TNF-α inhibitors",
      "attrs": {},
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30c9e124-a202-408c-99ba-871bb26a0fbc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.79,
        "x": 0.026,
        "y": 0.047
      },
      "kind": "title",
      "text": "Innovations in DED Lag in Comparison to Other Specialties",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce73f50c-a939-4d3d-afb4-20c55b99c0ed",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}